despit
avail
prophylact
vaccin
burden
human
papillomaviru
hpv
associ
malign
remain
high
need
develop
addit
therapeut
strategi
complement
vaccin
previous
shown
poorli
characteris
oncoprotein
form
viruscod
ion
channel
viroporin
sensit
amantadin
deriv
rimantadin
demonstr
alkyl
imino
sugar
antivir
activ
number
virus
inhibit
channel
activ
vitro
use
molecular
model
predict
imino
sugar
intercal
protom
prevent
channel
oligomeris
explor
abil
viroporin
inhibitor
block
activ
mitogen
signal
keratinocyt
treatment
either
rimantadin
imino
sugar
prevent
erkmapk
phosphoryl
reduc
cyclin
express
cell
express
number
highrisk
hpv
type
moreov
viroporin
inhibitor
also
reduc
erkmapk
activ
cyclin
express
differenti
primari
human
keratinocyt
contain
highrisk
observ
provid
evid
key
role
viroporin
function
hpv
life
cycl
viroporin
inhibitor
could
utilis
stratifi
treatment
hpv
associ
tumour
prior
viru
integr
true
antivir
therapi
elimin
viru
prior
malign
transform
human
papillomavirus
hpv
small
nonenvelop
doublestrand
dna
dsdna
virus
infect
squamou
epitheli
cell
sexual
transmit
caus
approxim
million
new
infect
per
year
usa
cate
mucos
lowrisk
hpv
type
caus
benign
anogenit
wart
wherea
limit
number
highrisk
hpv
type
caus
major
anogenit
cancer
well
subset
oropharyng
malign
respons
largest
proport
carcinoma
de
sanjos
et
al
prigg
et
al
walboom
et
al
prophylact
vaccin
avail
yet
protect
subset
hpv
type
littl
impact
upon
preexist
infect
schiller
moreov
hpv
vaccin
programm
poorli
avail
develop
countri
cervic
cancer
frequent
bruni
et
al
effect
antivir
agent
repres
altern
approach
treat
hpv
infect
yet
drug
current
avail
highrisk
hpv
encod
three
earli
oncogen
influenc
cellular
prolifer
differenti
surviv
moodi
laimin
function
well
characteris
major
driver
keratinocyt
prolifer
express
retain
within
tumour
contrast
less
well
understood
highrisk
express
induc
anchorageindepend
growth
murin
fibroblast
growth
low
serum
well
transform
primari
human
keratinocyt
et
al
mice
transgen
epitheli
express
display
hyperplasia
spontan
tumour
format
maufort
et
al
increas
cervic
dysplasia
maufort
et
al
mrna
highli
abund
hpv
lesion
stoler
et
al
http
receiv
march
receiv
revis
form
juli
accept
august
protein
like
express
earli
stage
malign
episom
viral
genom
present
chang
et
al
thu
repres
potenti
target
earli
stage
intervent
hpv
posit
cancer
potenti
epiderm
growth
factor
receptor
egfr
signal
result
enhanc
mitogen
activ
protein
kinas
mapk
activ
straight
et
al
wasson
et
al
modul
egfr
implic
pathogenesi
express
domin
neg
egfr
attenu
epitheli
hyperplasia
observ
mice
genther
william
et
al
gener
highrisk
hpv
genom
lack
express
identifi
key
role
product
stage
infect
fehrmann
et
al
genther
et
al
wasson
et
al
recent
egfr
activ
shown
critic
function
product
stage
hpv
lifecycl
wasson
et
al
absenc
egfr
signal
contain
keratinocyt
fail
maintain
cyclin
express
suprabas
layer
epithelium
instead
initi
default
differenti
programm
precis
egfr
signal
augment
unknown
may
involv
alkalinis
egfrcontain
endosom
prevent
degrad
result
recycl
activ
receptor
plasma
membran
straight
et
al
perturb
endosom
acidif
remain
unknown
belong
expand
group
viral
membran
protein
term
viroporin
royl
et
al
scott
griffin
small
protein
residu
contain
least
one
poreform
helix
oligomeris
creat
hydrophil
pore
across
membran
viroporin
perturb
host
cell
homeostasi
variou
stage
infect
often
involv
viral
entri
andor
releas
scott
griffin
howev
cellular
function
also
alter
protein
includ
vesicl
traffick
apoptosi
inhibit
viroporin
function
repres
ideal
target
antivir
drug
develop
scott
griffin
clinic
preced
set
prototyp
adamantan
drug
target
influenza
viru
iav
proton
channel
pinto
et
al
previous
demonstr
form
hexamer
viroporin
complex
activ
sensit
adamantan
rimantadin
well
novel
unrel
scaffold
wetheril
et
al
identifi
alkyl
imino
sugar
inhibitor
viroporin
activ
ensu
blockad
channel
activ
prevent
activ
erkmapk
result
diminish
cyclin
express
within
suprabas
keratinocyt
concomit
block
life
cycl
thu
target
channel
activ
repres
viabl
drug
target
potenti
antivir
antitumour
applic
express
glutathion
stransferas
gst
fusion
escherichia
coli
cell
cleav
purifi
describ
previous
wetheril
et
al
rhodaminelabel
liposom
compris
phosphatid
acid
phosphatidylcholin
contain
selfquench
concentr
carboxyfluorescein
cf
gener
describ
wetheril
et
al
induc
cf
releas
assess
realtim
fluorimetri
fluostar
optima
micropl
reader
bmg
technolog
excit
emiss
filter
set
nm
respect
reaction
typic
compris
protein
liposom
total
reaction
volum
hb
give
final
concentr
describ
wetheril
et
al
melittin
sigma
serv
posit
control
sampl
repeat
triplic
data
averag
endpoint
read
taken
initi
rate
calcul
initi
linear
dye
releas
kinet
fu
fluoresc
unit
compound
use
rimantadinehcl
sigma
hexamethylen
amilorid
hma
sigma
imino
sugar
deriv
nnonyl
deoxynojirimycin
nndnj
nnonyldeoxygalactonojirimycin
nbdgj
toronto
biochem
inhibitor
reconstitut
mm
stock
solut
dmso
dilut
appropri
media
buffer
secondari
structur
predict
use
psipr
http
bioinfcsuclacukpsipr
model
monom
construct
use
maestro
schroding
inc
previous
describ
wetheril
et
al
monom
built
amino
acid
amino
acid
energi
minim
merck
molecular
forc
field
mmff
simul
water
dielectr
monom
dock
oligom
subject
energi
minim
dock
complex
employ
ligprep
modul
maestro
schroding
dock
program
glide
friesner
et
al
ligpreptr
energyminim
ligand
dock
prepar
receptor
grid
bind
affin
evalu
glide
score
gscore
paramet
eldridg
et
al
bestdock
pose
select
one
lowest
gscore
highest
neg
valu
cell
maintain
describ
previous
et
al
transfect
primari
human
foreskin
keratinocyt
nhk
isol
neonat
foreskin
tissu
ethic
approv
perform
describ
previous
deluri
et
al
wilson
et
al
account
donorspecif
effect
cell
line
harbour
wild
type
knockout
genom
gener
nhk
isol
two
donor
contain
nhk
grown
complet
e
media
confluent
media
chang
serum
free
keratinocyt
media
without
supplement
sfm
medium
invitrogen
contain
mm
calcium
chlorid
cell
maintain
media
h
lysi
analysi
total
protein
extract
keratinocyt
lysi
buffer
mankouri
et
al
resolv
sdspage
trisglycin
transfer
onto
hybond
nitrocellulos
membran
amersham
bioscienc
probe
antibodi
specif
cyclin
santa
cruz
biotechnolog
santa
cruz
biotechnolog
abcam
cell
signal
technolog
gfp
santa
cruz
biotechnolog
gapdh
santa
cruz
biotechnolog
immunoblot
visual
speciesspecif
hrp
conjug
secondari
antibodi
sigma
ecl
reagent
thermopierc
cell
plate
plate
h
prior
treatment
inhibitor
cell
viabil
determin
h
posttreat
mtt
assay
describ
previous
samson
et
al
membran
lipid
pack
studi
use
fluoresc
probe
sigma
assess
degre
membran
insert
fluoresc
flow
cytometri
suzuki
et
al
williamson
et
al
gfp
transfect
cell
incub
h
detach
use
enzymefreepbsbas
cell
dissoci
buffer
cell
suspend
min
wash
thoroughli
pb
resuspens
pb
cell
surfac
fluoresc
analys
bd
fortessa
use
nm
excit
nm
emiss
wavelength
cell
transfect
use
polyethyleneimin
pei
reagent
describ
et
al
plasmid
express
gfp
combin
report
plasmid
human
cyclin
promot
drive
express
firefli
luciferas
wasner
et
al
constitut
express
renilla
luciferas
plasmid
use
assess
transfect
effici
transfect
cell
serum
starv
h
lyse
assay
luciferas
activ
use
dualluciferas
stop
glo
reagent
promega
luminomet
eg
g
berthold
describ
richard
et
al
appropri
cell
treat
rimantadin
nndnj
h
prior
analysi
assay
perform
triplic
fold
promot
activ
calcul
divid
rel
luciferas
activ
stimul
cell
mocktreat
cell
sever
prototyp
class
inhibitor
compound
shown
abrog
viroporin
function
vitro
includ
rimantadin
nonyl
imino
sugar
eg
nndnj
hexamethylen
amilorid
hma
scott
griffin
compound
sinc
shown
exert
antivir
effect
number
virus
includ
hcv
bvdv
dengu
sarscov
et
al
stgelai
et
al
wilson
et
al
wu
et
al
zitzmann
et
al
rimantadin
effect
block
activ
wetheril
et
al
examin
whether
prototyp
viroporin
inhibitor
might
block
viroporin
activ
vitro
liposom
dye
releas
assay
fig
wetheril
et
al
name
hma
long
alkylchain
imino
sugar
nndnj
short
alkylchain
imino
sugar
nbdgj
fig
interestingli
hma
treatment
enhanc
initi
rate
cf
releas
liposom
likewis
increas
endpoint
fluoresc
compar
dmso
control
fig
assay
triton
treatment
yield
maxim
fluoresc
increas
like
due
either
hma
induc
fusion
event
nonspecif
disrupt
liposom
hma
hold
channel
complex
open
conform
contrast
addit
nndnj
nbdgj
led
signific
reduct
cf
releas
liposom
measur
initi
rate
endpoint
fluoresc
fig
f
next
preincub
increas
concentr
nndnj
nndnj
potent
inhibit
viroporin
activ
dosedepend
fashion
fig
b
plot
percentag
initi
rate
plot
nndnj
approxim
nndnj
calcul
fig
confirm
imino
sugar
nonspecif
block
cf
releas
liposom
bee
venom
pore
form
peptid
melittin
incub
high
concentr
imino
sugar
impact
cf
releas
assess
endpoint
fluoresc
compar
melittin
control
neither
imino
sugar
exert
inhibitori
effect
cf
releas
fig
final
confirm
neither
imino
sugar
could
quench
cf
fluoresc
intens
incub
compound
liposom
prior
disrupt
use
triton
wv
expect
none
compound
display
abil
quench
fluoresc
fig
confirm
inhibit
proteinspecif
interrog
potenti
mode
inhibit
imino
sugar
revisit
previou
dock
studi
wetheril
et
al
determin
probabl
bind
mode
nndnj
nbdgj
use
glide
program
schroding
inhibitor
compound
dock
hexamer
model
glide
grid
extend
allow
free
dock
compound
entir
channel
surfac
unlik
previou
studi
rimantadin
occupi
lipophil
pocket
line
channel
lumen
wetheril
et
al
nndnj
instead
intercal
monom
protom
interfac
glidescor
kcalmol
fig
predict
disrupt
pi
stack
gener
fig
potenti
disrupt
oligomeris
protom
nbdgj
adopt
similar
bind
pose
although
locat
closer
pore
also
like
impair
monom
interact
disrupt
hydrogen
bond
supplementari
fig
nbdgj
similar
estim
glide
dock
score
nndnj
kcalmol
next
wish
assess
whether
viroporin
activ
conserv
featur
protein
hpv
type
ultim
determin
whether
contribut
biolog
function
cell
laboratori
begun
studi
function
protein
code
wasson
et
al
ask
question
like
also
possess
viroporin
activ
despit
rel
poor
model
channel
complex
gener
use
maestro
describ
materi
method
c
merocyanin
assay
perform
cell
transfect
gfp
cell
analys
bd
fortessa
cytomet
histogram
creat
use
flowjo
softwar
cell
transfect
e
f
parallel
gfp
control
cell
incub
rimantadin
nndnj
h
lysat
probe
antibodi
cyclin
phosphoryl
total
form
gfp
gapdh
serv
load
control
repres
blot
shown
least
three
independ
biolog
repeat
g
lysat
hela
cell
incub
rimantadin
nndnj
h
probe
antibodi
total
phosphoryl
form
cyclin
hpv
oncoprotein
load
control
gapdh
repres
blot
shown
least
three
independ
biolog
repeat
h
activ
cyclin
report
plasmid
cell
cotransfect
report
gfp
subsequ
treat
egf
rimantadin
nndnj
cell
lyse
passiv
lysi
buffer
promega
analys
use
dual
luciferas
system
promega
data
independ
biolog
repeat
present
fold
chang
compar
untreat
gfp
error
bar
standard
deviat
p
p
amino
acid
conserv
two
protein
share
similar
hydrophob
profil
indic
presenc
three
tmd
fig
silico
model
predict
format
analog
hexamer
channel
complex
fig
abl
purifi
recombin
use
standard
viroporin
purif
method
wetheril
et
al
unabl
undertak
vitro
liposom
assay
studi
protein
altern
strategi
set
examin
potenti
viroporin
activ
cell
assess
effect
membran
integr
use
lipophil
fluoresc
dye
merocyanin
provid
indirect
measur
lipid
pack
lelk
et
al
williamson
et
al
previous
use
investig
viroporin
function
suzuki
et
al
transfect
cell
assess
label
use
flow
cytometri
show
intens
cell
significantli
higher
gfp
express
cell
fold
increas
p
fig
suggest
disrupt
lipid
pack
modifi
structur
cellular
membran
consist
previou
observ
level
erkmapk
phosphoryl
total
protein
increas
express
cell
compar
gfp
alon
correl
increas
cyclin
express
fig
revers
addit
either
rimantadin
nndnj
nbdgj
supplementari
fig
due
cytotox
effect
inhibitor
supplementari
fig
similar
reduct
erk
phosphoryl
cyclin
level
observ
cell
express
protein
highrisk
fig
fig
type
treat
rimantadin
nndnj
yet
compound
alon
effect
upon
level
basal
erk
phosphoryl
cyclin
express
gfp
express
cell
fig
supplementari
fig
moreov
erk
phosphoryl
cyclin
express
also
unalt
hela
cell
hpv
posit
lack
treat
rimantadin
nndnj
fig
next
assay
human
cyclin
promot
driven
transcript
firefli
luciferas
wasner
et
al
cell
cotransfect
report
either
gfp
luciferas
activ
significantli
higher
express
cell
compar
gfp
alon
specif
revers
follow
treatment
either
rimantadin
nndnj
fig
accordingli
neither
rimantadin
nndnj
affect
luciferas
activ
gfpexpress
cell
stimul
egf
thu
specif
upregul
cyclin
express
follow
egfr
activ
sensit
structur
unrel
prototyp
viroporin
inhibitor
turn
display
offtarget
effect
upon
relev
pathway
henc
conclud
viroporin
activ
directli
respons
effect
final
assess
biolog
function
viroporin
activ
context
product
hpv
life
cycl
primari
human
keratinocyt
harbour
wildtyp
wt
genom
differenti
high
calcium
media
presenceabs
rimantadin
fig
nndnj
fig
nbdgj
supplementari
fig
inhibitor
abl
revers
retent
erk
phosphoryl
cyclin
express
presenc
differenti
stimuli
reduc
similar
level
observ
cell
harbour
genom
compar
lane
plu
consequ
loss
mitogen
signal
note
wild
type
cell
treat
viroporin
inhibitor
exhibit
increas
differenti
marker
express
thu
taken
togeth
data
demonstr
viroporin
activ
critic
mainten
mitogen
signal
delay
differenti
marker
express
observ
product
stage
life
cycl
work
provid
evid
link
viroporin
activ
high
risk
hpv
protein
type
critic
aspect
function
within
cell
also
show
alkyl
iminosugar
repres
second
class
prototyp
viroporin
inhibitor
compound
addit
previous
identifi
blocker
rimantadin
prevent
upregul
cyclin
express
via
effect
upon
egfr
activ
henc
repres
first
exampl
potenti
oncogen
viroporin
make
excel
prospect
target
antivir
stratifi
antitumour
strategi
treatment
long
short
chain
alkylchain
imino
sugar
deriv
reduc
viroporin
activ
vitro
particular
nndnj
exhibit
consider
vitro
potenc
ic
repres
improv
compar
previou
studi
rimantadin
bespok
scaffold
includ
wetheril
et
al
howev
potenc
compound
appear
similar
cellbas
assay
lowmid
micromolar
rang
reminisc
activ
vs
viroporin
prototyp
molecul
shown
activ
includ
eg
hepat
c
viru
iav
howev
whilst
lack
true
druglik
potenc
prototyp
viroporin
inhibitor
use
identifi
potenti
bind
site
inhibitori
mode
action
subsequ
target
via
ration
design
compound
screen
approach
unlik
rimantadin
nndnj
predict
intercal
protom
within
valid
molecular
model
channel
complex
suggest
interrupt
oligomeris
repres
potenti
inhibitori
mechan
compound
specif
nndnj
bind
channel
predict
disrupt
pi
stack
gener
reduc
stabil
protomerprotom
bind
interestingli
align
amino
acid
sequenc
identifi
equival
phe
residu
mucos
hpv
type
suggest
residu
mediat
oligomeris
nndnj
may
potenti
crossact
sever
hpv
type
similarli
nndnj
shown
prevent
hcv
oligomeris
similar
interprotom
bind
site
predict
dock
studi
foster
et
al
bind
site
valid
coloc
resist
polymorph
within
site
identifi
innat
nndnj
resist
genotyp
employ
similar
modellingdock
strategi
herein
highlight
potenti
mechanist
similar
oligomeris
investig
lastli
notabl
shorter
chain
imino
sugar
eg
nbdgj
could
inhibit
viroporin
activ
vitro
compound
ineffect
viroporin
includ
steinmann
et
al
analysi
nbdgj
bind
mode
suggest
also
interact
protom
interfac
would
like
interfer
channel
oligomeris
satisfi
rimantadin
imino
sugar
repres
inhibitor
channel
function
employ
tool
dissect
potenti
link
viroporin
activ
key
aspect
function
within
cell
role
hpvassoci
cancer
remain
poorli
defin
hpv
genom
often
becom
integr
malign
progress
disrupt
orf
assum
might
play
cancerpromot
role
rather
drive
progress
persist
posttransform
howev
signific
number
cervic
cancer
contain
unintegr
hpv
genom
much
lower
frequenc
viral
dna
integr
occur
hpv
posit
hnscc
olthof
et
al
moreov
protein
detect
mass
spectrometri
cervic
cancer
cell
line
contain
integr
hpv
genom
sahab
et
al
therefor
express
like
persist
within
subset
advanc
hpv
posit
tumour
could
expedit
stratif
therapi
patient
consist
grow
recognit
constitut
potenti
therapeut
target
kim
yang
maufort
et
al
major
aspect
oncogen
function
activ
egfr
signal
drive
cyclin
express
via
erk
suprabas
layer
epithelium
wasson
et
al
interestingli
like
involv
alkalinis
egfrcontain
endosom
origin
ascrib
interact
cellular
vatpas
conrad
et
al
yet
thought
case
suprynowicz
et
al
previou
observ
acid
ph
activ
channel
activ
vitro
reminisc
viroporin
serv
promot
vesicl
alkalinis
consist
similar
role
high
risk
cell
treatment
express
keratinocyt
cell
harbour
fulllength
hpv
genom
rimantadin
imino
sugar
prevent
increas
cyclin
b
express
concomit
erk
phosphoryl
inhibitor
obviou
offtarget
effect
neither
cell
express
gfp
alon
hpvtransform
cell
line
integr
genom
lack
show
modul
pathway
upon
treatment
observ
consist
three
highrisk
hpv
type
suggest
link
viroporin
activ
least
one
major
aspect
prooncogen
function
directli
link
taken
togeth
data
support
uniqu
amongst
viroporin
exampl
known
date
channel
activ
direct
role
regul
cellular
prolifer
potenti
also
malign
transform
identif
prototyp
inhibitor
suggest
druggabl
site
exist
within
channel
complex
could
exploit
dedic
small
molecul
drug
discoveri
programm
could
lead
new
therapeut
option
stratifi
patient
tumour
maintain
express
inde
antivir
strategi
hpv
posit
individu
prior
onset
malign
prototyp
viroporin
inhibitor
distinct
chemotyp
effect
inhibitor
viroporin
activ
vitro
primari
cell
cultur
model
abolish
erkmapk
activ
reduc
cyclin
express
distinct
mode
action
adamantan
versu
imino
sugar
provid
scope
develop
parallel
yet
complementari
inhibitor
seri
could
compris
combin
therapi
could
utilis
stratifi
treatment
hpv
associ
tumour
prior
viru
integr
true
antivir
therapi
elimin
viru
prior
malign
transform
author
declar
conflict
interest
work
fund
grant
cancer
research
uk
medic
research
council
mrc
biotechnolog
biolog
scienc
research
council
bbsrc
studentship
dk
wellcom
trust
studentship
gs
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
thank
kurt
engeland
univers
leipzig
provid
human
luciferas
report
plasmid
joseph
spitzer
fig
viroporin
inhibitor
prevent
mediat
mitogen
signal
context
product
infect
primari
human
keratinocyt
contain
wild
type
genom
differenti
high
calcium
media
h
presenc
absenc
rimantadin
b
nndnj
cell
lysat
probe
antibodi
cyclin
phosphoryl
total
form
filaggrin
gapdh
load
control
repres
blot
shown
least
three
independ
biolog
repeat
graph
repres
densitometri
analysi
cyclin
phosphoryl
erk
level
h
time
point
untreat
drugtreat
wild
type
cell
graph
repres
data
three
independ
repeat
p
p
p
patient
collect
donat
foreskin
tissu
supplementari
data
relat
articl
found
http
